New Drug Approvals
New drug approvals - January 2024
Audiences
Healthcare professional
Industry member
Product type
Therapeutic Products
13 February 2024
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
Please click here for a list of summary reports of benefit-risk assessments.
Table caption
Product Name | GENCEBOK SOLUTION FOR INFUSION 10MG/ML |
|---|---|
Active Ingredient (Strength) | Caffeine Citrate(10.00mg/ml) |
Application type | NDA-2 |
Product Registrant | AXXESSBIO PTE. LTD. |
Date of Approval | 16/01/2024 |
Registration No. | SIN16929P |
Indications: Treatment of primary apnoea of premature newborns. | |
Table caption
Product Name | LUMIGAN PF (BIMATOPROST OPHTHALMIC SOLUTION) 0.03% |
|---|---|
Active Ingredient (Strength) | Bimatoprost(0.3 mg/mL) |
Application type | NDA-2 |
Product Registrant | ABBVIE PTE. LTD. |
Date of Approval | 30/01/2024 |
Registration No. | SIN16938P |
Indications: LUMIGAN® Preservative Free 0.03% (bimatoprost ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. | |